Early-phase data are signaling a long-awaited breakthrough in pancreatic ductal adenocarcinoma, with novel KRAS inhibitors showing meaningful activity in heavily pretreated patients. Monotherapy with next-generation KRAS-targeted agents has produced response rates near 40%, an unprecedented signal in a disease historically limited to chemotherapy alone. Drs. Hornstein, Brown, and Grewal explore why these results represent a true inflection point for a mutation present in over 90% of pancreatic cancers. With manageable toxicity and oral administration, KRAS-directed therapy may soon redefine treatment options for one of oncology’s toughest diseases.
